NeoGenomics (NASDAQ:NEO) PT Raised to $19.00 at The Goldman Sachs Group

NeoGenomics NASDAQNEO is a medical research company that specializes in genetic testing and diagnostics. The company's stock was recently raised to $19.00 at The Goldman Sachs Group, which is a leading investment bank and financial services firm.

In a research note issued on Thursday, The Goldman Sachs Group analysts lifted the price target for NeoGenomics NASDAQNEO from $17.00 to $19.00. This indicates that they believe the stock is undervalued and has potential for growth.

The brokerage currently has a "buy" rating on the company's stock, which means they recommend investors buy NeoGenomics NASDAQNEO shares. The Goldman Sachs Group's target price suggests that the stock could potentially increase in value by [insert percentage or amount].

It is important to note that stock prices can be volatile and subject to change based on various factors, including market conditions, company performance, and news events. As such, investors should always conduct their own research and consider seeking advice from a financial advisor before making any investment decisions.